CMS J-Code for Glaukos’ iDose TR Becomes Active

Glaukos Corporation has confirmed the activation of the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for its iDose TR product. This development marks a significant milestone in enhancing patient access and streamlining coverage and payment processes for the innovative treatment, according to the company.

Simplifying Coverage and Payment Processes

The J-code assignment is expected to simplify coverage across the United States, ensuring consistent reimbursement and facilitating broader access to iDose TR. Glaukos anticipates that healthcare providers will benefit from a more predictable payment process, thereby supporting seamless integration into patient care pathways.

Glaukos initially disclosed the assignment of the J-code by CMS in April, designating it for iDose TR (travoprost intracameral implant) 75 mcg. This prostaglandin analog is specifically indicated for reducing intraocular pressure in individuals diagnosed with ocular hypertension (OHT) or open-angle glaucoma (OAG).

Milestones and Regulatory Approvals

The FDA granted approval for iDose TR in December 2023, underscoring its status as a long-duration, intracameral procedural pharmaceutical therapy. The product is engineered to deliver sustained therapeutic levels of Glaukos’ proprietary travoprost formulation within the eye, providing continuous treatment for OHT and OAG. Glaukos highlights that this approach aims to improve treatment adherence and reduce the burden on patients undergoing ocular therapy.

The activation of the J-code represents a critical step forward as Glaukos progresses with its commercial launch strategy for iDose TR, reinforcing its commitment to advancing ophthalmic care through innovative solutions.

Ocular Hypertension & Open-Angle Glaucoma

Ocular hypertension (OHT) and open-angle glaucoma (OAG) are both conditions that affect the eyes and can lead to vision impairment if left untreated. Ocular hypertension is characterized by higher than normal intraocular pressure without any optic nerve damage or vision loss. It is considered a significant risk factor for the development of glaucoma.

Open-angle glaucoma, on the other hand, is a progressive optic neuropathy where the drainage angle of the eye remains open but becomes less efficient over time, leading to increased intraocular pressure and damage to the optic nerve. Both conditions require ongoing management to control intraocular pressure and prevent further vision deterioration, often through medications like prostaglandin analogs such as Glaukos’ iDose TR, surgical interventions, or other therapeutic approaches aimed at preserving vision and quality of life.